Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reissue Patent
2007-01-23
2007-01-23
Cook, Rebecca (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S387000
Reissue Patent
active
09912472
ABSTRACT:
A method for treating Type II diabetes by administering to an affected individual a combination of chromic tripicolinate and biotin. The two compounds are administered orally or parenterally at in daily dosages which provide between 50 and 1,000 μg of chromium and between 25 μg and 200 mg biotin, the amounts of chromium and biotin being selected together to provide a greater than additive effect.
REFERENCES:
patent: 4315927 (1982-02-01), Evans
patent: 5087623 (1992-02-01), Boynton et al.
patent: 5336672 (1994-08-01), Southern, Jr. et al.
patent: 5470846 (1995-11-01), Sandyk
patent: 5496827 (1996-03-01), Patrick
patent: 5597585 (1997-01-01), Williams et al.
patent: 5635535 (1997-06-01), Wagstaff
patent: 5789401 (1998-08-01), McCarty
patent: 6048846 (2000-04-01), Cochran
patent: 6140304 (2000-10-01), Sears
patent: WO 91/11117 (1991-08-01), None
patent: WO 96/25939 (1996-08-01), None
patent: WO 96/35421 (1996-11-01), None
patent: WO 99/07387 (1999-02-01), None
patent: WO 02/11564 (2002-02-01), None
Coggeshall, et al. (1985) Biotin status and plasma glucose in diabetics.Ann. N.Y. Acad. Sci.447:389-392.
Maebashi, et al. (1993) Therapeutic evaluation of the effect of biotin on hyperglycemia in patients with non-insulin dependent diabetes mellitus.J. Clin. Biochem. Nutr.14:211-218.
Mock, D. (1984)In Present Knowledge in Nutrition,7thEdition, Chapter 22, pp. 220-235.
Reddi, et al. (1988) Biotin supplementation improves glucose and insulin tolerances in genetically diabetic kk mice.Life Sciences.42:1323-1330.
Zhang, et al. (1996) A high biotin improves the impaired glucose tolerance of long-term spontaneously hyperglycemic rats with non-insulin-dependent diabetes mellitus.J. Nutri. Sci. Vitaminol.42:517-526.
Zhang, et al.(1997) Biotin administration improves the impaired glucose tolerance of streptozotocin-induces diabetic Wistar rats.J. Nutri. Sci. Vitaminol.43(3):271-280.
Copy of label from Multi-Vitamin suppl. “alpha-betic™”.
Copy of label from Multi-Vitamin suppl. “Mega Men©”.
Anderson, R.A. (1997) Nutritional factors influencing the glucose/insulin system: Chromium. Journal of the American College of Nutrition. 16(5):404-410.
Cefalu et al. (1997) The effect of chromium supplementation on carbohydrate metabolism and body fat distribution. Diabetes. 46:55a.
Maebashi et al. (1993) Therapeutic evaluation of the effect of biotin on hyperglycemia in patients with non-insulin dependent diabetes mellitus. J. Clin. Biochem, Nutr. 14:211-218.
McCarty (1991) The case for supplemental chromium and a survey of clinical studies wiht chromium picolinate. Journal of Applied Nutrition. 43(1):58-66.
Ravina et al. (1995) Clinical use of the trace element chromium (III) in the treatment of diabetes mellitus. The Journal of Trace Elements in Experimental Medicine. 8:183-190.
McCarty, Mark F. “Dietary glycemic index may influence cancer risk by modulating IGF-1 activity: a hypothesis.”Journal of Medicinal Food.1(2): 123-140 (1998).
Cook Rebecca
Knobbe Martens Olson & Bear LLP
Nutrition 21, Inc.
LandOfFree
Chromium/biotin treatment of type II diabetes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chromium/biotin treatment of type II diabetes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chromium/biotin treatment of type II diabetes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3763413